DARE Stock — Dare Bioscience Inc

Dare Bioscience Inc (DARE)

Updated October 16, 2026.

DARE is a Stock. Total return is -99.9% over the past 12.5 years, 513.3 points behind SPY at 413.4%.

Daré Bioscience develops therapies focused on women's health, including treatments for contraception, pelvic pain, fertility, menopause, sexual health, and infectious diseases; its approved product XACIATO treats bacterial vaginosis, while its pipeline includes candidates for conditions ranging from female sexual arousal disorder to preterm birth prevention. The company does not currently distribute to shareholders. This company appeals primarily to investors seeking exposure to early-stage pharmaceutical development in the women's health space rather than those seeking current income.

DARE performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.9% over the past 12.5 years, 513.3 points behind SPY at 413.4%. Over the past year its total return — price change plus distributions reinvested — is -65.8%. Its deepest 1-year drawdown was 78.4%.

DARE key facts

Asset type

Stock

Asset class

Equity

Inception date

04/10/2014

Distribution frequency

None

Last close

$0.72 (as of 2026-10-16)

Market cap

$14,252,218

Average volume

77207.0

Payment date

07/20/2017

Beta

1.009

Payout ratio

0.0%

Forward P/E

1.2682

EPS

$-0.71

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

DARE risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 78.4%.

Who may consider DARE — and who may not

It is a weaker fit for investors who need monthly cash flow (DARE does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on DARE

• All tickers starting with D

Tagged: Healthcare.

Frequently asked questions